Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
CAR-T Cell Therapies at EULAR 2026
EurekAlert!
In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-
Read Article
EULAR26 Insights into Gout and Obesity
EurekAlert!
New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied
Read Article
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u
Dr. John Cush @RheumNow( View Tweet )
Late-Breaking Studies at EULAR 2026
MedPage Today
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical
Read Article
Long-term Cancer Risk with Targeted Therapy in SpA
Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London
https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12
Read Article
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF
Read Article
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
How many CAR-T’s do we need to test drive?
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Read Article
Lessons on Non-adherence
Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences
Read Article
A bridge to uncertainty?
large #RCT of #baricitinib V #TNFi
In
Active #RA w #DVT/#VTE risk factor(s)
Sl more VTE, #infection #SIE on #Bar
NO increase #MACE
Sl ⬆️#malignancy
#VTE rate exceeded upper limit of a priori #CI
So is this good news or not?
#LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
Janet Pope @Janetbirdope( View Tweet )
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and
Read Article
Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults.
"Steroids and Me" (Sam) provides online patient education ~5 minutes.
@RheumNow #EULAR2026 POS1388
Jiha Lee @JihaRheum( View Tweet )
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Dr. John Cush @RheumNow( View Tweet )
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.
SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)
A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile
Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk:
-VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile)
-No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t
Links:
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://x.com/Janetbirdope/status/2063179861397536847/photo/1
- https://twitter.com/eular_ard/status/2062509665024344391
Janet Pope @Janetbirdope( View Tweet )
Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.
Identifying high-risk pts and individualizing tx is paramount.
LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
Links:
sheila @RHEUMarampa( View Tweet )
Abstr LB0009
Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.
VTE: HR 1.61 (95% CI 0.97–2.66)
non-inferiority not demonstrated
MACE: HR 1.06 no cardiovascular excess
Serious infections: HR 1.32 (p<0.05)
@RheumNow https://t.co/NSNRJi9B4r
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Abstr LB0009
Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years.
Safety endpoints
VTE HR 1.61 non inferiority not met
Serious infections HR 1.32 (p<0.05)
MACE HR 1.06 reassuring
@RheumNow #EULAR2026 https://t.co/nR6TMowlYS
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Immune Dimming or Immune Reset in RA: How Far Should We Go?
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of
Read Article
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66).
But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009
Jiha Lee @JihaRheum( View Tweet )
Therapeutic Updates
Lupus Nephritis
Sponsored by RheumNow
View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.
Read Post
Recent Blogs
Podcasts
ACR 2025 Daily Podcasts Day2d
EULAR 2021 - Day2b00:35:57
